Healthcare software provider Syapse has raised $10 million in a Series B round of financing, the company announced today.
Diseases such as cancer often require complex, precise care. Syapse is dedicated to improving how medical professionals diagnose and treat these conditions.
It can be challenging for clinicians to make diagnosis and treatment decisions when critical data is housed in electronic medical records. So Syapse has developed the Syapse Precision Medicine Data Platform, which analyzes information from electronic medical records, molecular testing labs, and billing systems to assist medical professionals with diagnoses, treatment, and patient outcome tracking.
“As we continue to gain experience and momentum in working with some of the leading medical institutions in the world, we are as convinced as ever that the opportunity to positively impact healthcare through precision medicine software is very real and quite massive,” said Glenn Winokur, CEO and co-founder of Syapse.
Healthcare venture capital firm Safeguard Scientifics and The Social+Capital Partnership led the new funding. The Social+Capital Partnership, a partnership of philanthropists, technologists and capitalists using venture capital to support businesses like Syapse, had participated in the Series A round of financing as well.
Syapse will be putting the money toward expanding sales, marketing, client services, and product development.
Syapse is headquartered in Palo Alto, Calif. The company recently partnered with Intermountain Healthcare to provide cancer treatment planning software to the medical community. Syapse will be creating an interface that allows oncologists to make better treatment decisions for their patients, which can potentially save lives.